Successful use of the sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with renal transplant and diabetes: a case series and literature review

Management of patients with diabetes and renal transplant could be challenging. Transplant patients use multiple immune suppressants that can worsen or even trigger hyperglycemia. There are no data about the use of the new class of sodium-glucose co-transporter-2 (SGLT-2) inhibitor dapagliflozin in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gul, Wajiha, Naem, Emad, Elawad, Safa, Elhadd, Tarik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575439/
https://www.ncbi.nlm.nih.gov/pubmed/34765893
http://dx.doi.org/10.1097/XCE.0000000000000246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575439/
https://www.ncbi.nlm.nih.gov/pubmed/34765893
http://dx.doi.org/10.1097/XCE.0000000000000246

Ejemplares similares